Roth Mkm Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)

Roth Mkm started coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report released on Friday,Benzinga reports. The brokerage issued a buy rating and a $7.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $11.25.

Reviva Pharmaceuticals Price Performance

Reviva Pharmaceuticals stock opened at $1.88 on Friday. The firm has a market capitalization of $62.87 million, a P/E ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83. The business has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.29.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.